Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7

Vaccine

Volumn 28, Issue 16, 2010, Pages 2810-2817

  Adachi, Katsuyuki ^a   Kawana, Kei ^a   Yokoyama, Terufumi ^b   Fujii, Tomoyuki ^a   Tomio, Ayako ^a   Miura, Shiho ^a   Tomio, Kensuke ^a   Kojima, Satoko ^a   Oda, Katsutoshi ^a   Sewaki, Tomomitsu ^b   Yasugi, Toshiharu ^a   Kozuma, Shiro ^a   Taketani, Yuji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Okinawa Industry Support Center   (Japan)

Author keywords

HPV therapeutic vaccine; Lactobacillus based vaccine; Mucosal cellular immune response; Oral immunization

Indexed keywords

GAMMA INTERFERON; GRANZYME B; PROTEIN E7; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; C57BL 6 MOUSE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNIZATION; INTESTINE MUCOSA; LACTOBACILLUS CASEI; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION;

ADMINISTRATION, ORAL; ANIMALS; BACTERIAL VACCINES; FEMALE; GENETIC VECTORS; IMMUNITY, MUCOSAL; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; LACTOBACILLUS CASEI; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 77949652815     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.005     Document Type: Article

References (44)

1. Ferlay J., Bray F., and Pisani P. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, version 2.0 (2004), IARC Press, Lyon
2. Moscicki A.B., Hills N., Shiboski S., Powell K., Jay N., Hanson E., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285 23 (2001) 2995-3002
3. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 87 11 (1995) 796-802
4. Kulasingam S.L., Hughes J.P., Kiviat N.B., Mao C., Weiss N.S., Kuypers J.M., et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288 14 (2002) 1749-1757
5. Ho G.Y., Burk R.D., Klein S., Kadish A.S., Chang C.J., Palan P., et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87 18 (1995) 1365-1371
6. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24 27-28 (2006) 5571-5583
7. Ault K.A. Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol 107 2 (2007) 27-30
8. Trimble C.L., and Frazer I.H. Development of therapeutic HPV vaccines. Lancet Oncol 10 10 (2009) 975-980
9. Poo H., Pyo H.M., Lee T.Y., Yoon S.W., Lee J.S., Kim C.J., et al. Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice. Int J Cancer 119 7 (2006) 1702-1709
10. van der Burg S.H., Kwappenberg K.M., O'Neill T., Brandt R.M., Melief C.J., Hickling J.K., et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 19 27 (2001) 3652-3660
11. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23 9 (1993) 2242-2249
12. Kaufmann A.M., Nieland J.D., Jochmus I., Baur S., Friese K., Gabelsberger J., et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 121 12 (2007) 2794-2800
13. Fiander A.N., Tristram A.J., Davidson E.J., Tomlinson A.E., Man S., Baldwin P.J., et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 16 3 (2006) 1075-1081
14. Roman L.D., Wilczynski S., Muderspach L.I., Burnett A.F., O'Meara A., Brinkman J.A.., et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 106 3 (2007) 558-566
15. García-Hernández E., González-Sánchez J.L., Andrade-Manzano A., Contreras M.L., Padilla S., Guzmán C.C., et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 13 6 (2006) 592-597
16. Garcia F., Petry K.U., Muderspach L., Gold M.A., Braly P., Crum C.P., et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 103 2 (2004) 317-326
17. Ressler S., Scheiden R., Dreier K., Laich A., Müller-Holzner E., Pircher H., et al. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin Cancer Res 13 23 (2007) 7067-7072
18. Cortes-Perez N.G., Lefèvre F., Corthier G., Adel-Patient K., Langella P., and Bermúdez-Humarán L.G. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine 25 36 (2007) 6581-6588
19. Neutra M.R., Pringault E., and Kraehenbuhl J.P. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu Rev Immunol 14 (1996) 275-300
20. Csencsits K.L., Jutila M.A., and Pascual D.W. Nasal-associated lymphoid tissue: phenotypic and functional evidence for the primary role of peripheral node addressin in naive lymphocyte adhesion to high endothelial venules in a mucosal site. J Immunol 163 3 (1999) 1382-1389
21. Hänninen A., Taylor C., Streeter P.R., Stark L.S., Sarte J.M., Shizuru J.A., et al. Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium. J Clin Invest 92 5 (1993) 2509-2515
22. Kelly K.A., and Rank R.G. Identification of homing receptors that mediate the recruitment of CD4 T cells to the genital tract following intravaginal infection with Chlamydia trachomatis. Infect Immun 65 12 (1997) 5198-5208
23. Mantis N.J., and Wagner J. Analysis of adhesion molecules involved in leukocyte homing into the basolateral pockets of mouse Peyer's patch M cells. J Drug Target 12 2 (2004) 79-87
24. Hawkins R.A., Rank R.G., and Kelly K.A. Expression of mucosal homing receptor alpha4beta7 is associated with enhanced migration to the Chlamydia-infected murine genital mucosa in vivo. Infect Immun 68 10 (2000) 5587-5594
25. Kunisawa J., Gohda M., and Kiyono H. Uniqueness of the mucosal immune system for the development of prospective mucosal vaccine. Yakugaku Zasshi 127 2 (2007) 319-326
26. Kajikawa A., Satoh E., Leer R.J., Yamamoto S., and Igimi S. Intragastric immunization with recombinant Lactobacillus casei expressing flagellar antigen confers antibody-independent protective immunity against Salmonella enterica serovar Enteritidis. Vaccine 25 18 (2007) 3599-3605
27. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 1 (1996) 21-26
28. Sakaue G., Hiroi T., Nakagawa Y., Someya K., Iwatani K., Sawa Y., et al. HIV mucosal vaccine: nasal immunization with gp160-Encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody Responses1. J Immunol 170 1 (2003) 495-502
29. Ishikawa H., Li Y., Abeliovich A., Yamamoto S., Kaufmann S.H., and Tonegawa S. Cytotoxic and interferon g-producing activities of gdT cells in the mouse intestinal epithelium are strain dependent. Proc Natl Acad Sci USA 90 17 (1993) 8204-8208
30. Dupuy C., Buzoni-Gatel D., Touzé A., Bout D., and Coursaget P. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 73 11 (1999) 9063-9071
31. Klavinskis L.S., Barnfield C., Gao L., and Parker S. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 162 1 (1999) 254-262
32. Stagg A.J., Kamm M.A., and Knight S.C. Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. Eur J Immunol 32 5 (2002) 1445-1454
33. Rank R.G., Bowlin A.K., and Kelly K.A. Characterization of lymphocyte response in the female genital tract during ascending Chlamydial genital infection in the guinea pig model. Infect Immun 68 9 (2000) 5293-5298
34. Cohen M.S., and Anderson D.J. Genitourinary mucosal defenses. In: Holmes K.K., Mardh P.A., Sparling P.F., Wiesner P.J., Cates Jr. W., Lemon S.M., and Stamm W.E. (Eds). Sexually transmitted diseases. 3rd ed. (1999), McGraw-Hill, New York 173-190
35. Lund J.M., Linehan M.M., Iijima N., and Iwasaki A. Plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection. In Situ J Immunol 177 11 (2006) 7510-7514
36. Soderberg K.A., Linehan M.M., Ruddle N.H., and Iwasaki A. MAdCAM-1 expressing sacral lymph node in the lymphotoxin beta-deficient mouse provides a site for immune generation following vaginal herpes simplex virus-2 infection. J Immunol 173 3 (2004) 1908-1913
37. Stoddard E., Cannon G., Ni H., Karikó K., Capodici J., Malamud D., et al. Vaginal submucosal dendritic cells, but not langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J Immunol 179 5 (2007) 3126-3132
38. Kraus I., Molden T., Ernø L.E., Skomedal H., Karlsen F., and Hagmar B. Human papillomavirus oncogenic expression in the dysplastic portio: an investigation of biopsies from 190 cervical cones. Br J Cancer 90 7 (2004) 1407-1413
39. Levine M.M., and Dougan G. Optimism over vaccines administered via mucosal surfaces. Lancet 351 9113 (1998) 1375-1376
40. Mohamadzadeh M., Olson S., Kalina W.V., Ruthel G., Demmin G.L., Warfield K.L., et al. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci USA 102 8 (2005) 2880-2885
41. Koizumi S., Wakita D., Sato T., Mitamura R., Izumo T., Shibata H., et al. Essential role of Toll-like receptors for dendritic cell and NK1.1(+) cell-dependent activation of type 1 immunity by Lactobacillus pentosus strain S-PT84. Immunol Lett 120 1-2 (2008) 14-19
42. Liu B., Ye D., Song X., Zhao X., Yi L., Song J., et al. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine 26 10 (2008) 1387-1396
43. Bian T., Wang Y., Lu Z., Ye Z., Zhao L., Ren J., et al. Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice. Mol Cancer Ther 7 5 (2008) 1329-1335
44. Boursnell M.E., Rutherford E., Hickling J.K., Rollinson E.A., Munro A.J., Rolley N., et al. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14 16 (1996) 1485-1494